| scholarly article | Q13442814 |
| P50 | author | Lori L. Altshuler | Q22003115 |
| Mauricio Tohen | Q88971056 | ||
| Carlos A Zarate | Q89052847 | ||
| Trisha Suppes | Q97540231 | ||
| P2093 | author name string | Denai R Milton | |
| Alan Breier | |||
| Julie A Gilmore | |||
| Richard Risser | |||
| Robert W Baker | |||
| Gary A Tollefson | |||
| Terrence A Ketter | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1011-1017 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Olanzapine versus divalproex in the treatment of acute mania | |
| P478 | volume | 159 |
| Q35236966 | Acute and long-term treatment of mania. |
| Q35618427 | Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics |
| Q36905879 | Adjunctive treatment of acute mania: a clinical overview |
| Q35111576 | Advances in the pharmacologic treatment of bipolar depression |
| Q34553398 | Anticonvulsants and antipsychotics in the treatment of bipolar disorder |
| Q36827444 | Antiepileptic drugs and mood stability. |
| Q45207634 | Antipsychotics in bipolar disorders |
| Q36797200 | Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights |
| Q21260276 | Atypical antipsychotics in bipolar disorder: systematic review of randomised trials |
| Q35124712 | Atypical antipsychotics in the treatment of bipolar disorder |
| Q36158824 | Atypical antipsychotics: newer options for mania and maintenance therapy |
| Q34547920 | Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder |
| Q57244668 | Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder |
| Q37165573 | Bipolar disorders: treatment options and patient satisfaction |
| Q51910730 | Calming the bipolar storm: treating acute mania and mixed episodes in patients with bipolar disorder. |
| Q52656684 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. |
| Q22252432 | Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania — A systematic review and meta-analysis |
| Q43266422 | Cost-effectiveness and HRQOL outcomes of divalproex sodium (Depakote) in bipolar disorder |
| Q34100578 | Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context |
| Q36905876 | Depot antipsychotic medications in bipolar disorder: a review of the literature |
| Q36106940 | Divalproex sodium in the treatment of adults with bipolar disorder |
| Q33820164 | Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention |
| Q37254782 | Drug-induced hyperphagia: what can we learn from psychiatric medications? |
| Q44783760 | Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial |
| Q24601815 | Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials |
| Q35999567 | Efficacy of atypical antipsychotics in bipolar disorder |
| Q33985398 | Efficacy of atypical antipsychotics in depressive syndromes |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q36634257 | Emerging drugs for bipolar disorder |
| Q34342857 | Everyday functional ability across different phases of bipolar disorder |
| Q36568973 | How assess drugs in the treatment of acute bipolar mania? |
| Q33355808 | Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach |
| Q33518859 | Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. |
| Q83200405 | Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers |
| Q33529314 | Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis |
| Q38243695 | Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. |
| Q35872066 | New medication treatment options for bipolar disorders |
| Q37954390 | Obesity and psychotropics. |
| Q24250164 | Olanzapine alone or in combination for acute mania |
| Q39853966 | Olanzapine for the Treatment of Bipolar Disorder |
| Q40501461 | Olanzapine in bipolar disorder |
| Q35669961 | Olanzapine-valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group |
| Q36390846 | Olanzapine/fluoxetine combination for bipolar depression |
| Q36273449 | Olanzapine: a critical review of recent literature |
| Q35945257 | Olanzapine: a review of its use in the management of bipolar I disorder |
| Q56791028 | Olanzapine: review of safety 2008 |
| Q39383213 | Patterns of atypical antipsychotic therapy use in adults with bipolar I disorder in the USA. |
| Q34432196 | Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration |
| Q44266758 | Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania |
| Q36361982 | Polytherapy in bipolar disorder |
| Q35746806 | Psychiatric medication-induced obesity: a review |
| Q35613754 | Psychotic bipolar disorders: dimensionally similar to or categorically different from schizophrenia? |
| Q24643545 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder |
| Q44874572 | Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study |
| Q92001769 | Recent advances in the biological treatment of mood disorders |
| Q35547289 | Recent developments in the treatment of bipolar disorders |
| Q37954423 | Refractoriness in bipolar disorder: definitions and evidence-based treatment |
| Q34017685 | Repeated assessment of exploration and novelty seeking in the human behavioral pattern monitor in bipolar disorder patients and healthy individuals |
| Q44957587 | Response to clozapine of rapid cycling versus non-cycling patients with a history of mania |
| Q24657398 | Review of olanzapine in the management of bipolar disorders |
| Q45336273 | Revised Korean medication algorithm for bipolar disorder. |
| Q33755661 | Role of extended release quetiapine in the management of bipolar disorders |
| Q38584632 | Safety and tolerability of anticonvulsant medication in bipolar disorder |
| Q35618441 | Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. |
| Q36199036 | Safety and tolerability of emerging pharmacological treatments for bipolar disorder |
| Q36691749 | Spectrum of effectiveness of valproate in neuropsychiatry |
| Q46552751 | Spotlight on olanzapine in bipolar I disorder |
| Q37858609 | Study design and patient characteristics and outcome in acute mania clinical trials |
| Q58760344 | Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q34550618 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment |
| Q34649187 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder |
| Q35775218 | The case for atypical antipsychotics in bipolar disorder |
| Q44408619 | The efficacy of olanzapine monotherapy for acute hypomania or mania in an outpatient setting |
| Q35779335 | The pharmacology of bipolar disorder during pregnancy and breastfeeding |
| Q33619910 | The psychopathology and treatment of bipolar disorder |
| Q39888212 | The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination |
| Q45070780 | The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research |
| Q28236713 | The role of atypical antipsychotics in bipolar depression and anxiety disorders |
| Q36235502 | The safety and tolerability of atypical antipsychotics in bipolar disorder |
| Q54190497 | The use of anticonvulsants in the aftermath of mania. |
| Q36606791 | The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials |
| Q42412787 | The use of atypical antipsychotics in Bipolar Spectrum disorders |
| Q35673093 | Treatment of acute mania |
| Q36162402 | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder |
| Q35613758 | Treatment of non-schizophrenic disorders: focus on atypical antipsychotics |
| Q36106843 | Use of olanzapine in the treatment of bipolar I disorder |
| Q34264093 | Valproate in acute mania: is our practice evidence based? |
| Q37865505 | Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. |
| Q37171035 | Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. |
| Q34557537 | Weight gain, obesity, and psychotropic prescribing |
Search more.